Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Phase 2

Active, not recruiting

Conditions: Grade 2 Follicular Lymphoma
Grade 3a Follicular Lymphoma
Recurrent Follicular Lymphoma
Grade 1 Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions: Procedure: Biopsy
Drug: Bendamustine Hydrochloride
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Drug: Lenalidomide
Drug: Cyclophosphamide
Biological: Obinutuzumab
Drug: Doxorubicin Hydrochloride
Procedure: Positron Emission Tomography
Drug: Umbralisib
Drug: Prednisone
Drug: Vincristine Sulfate

First Posted Date: 2017-09-01

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 95

Registration Number: NCT03269669

Locations: 🇺🇸
Longmont United Hospital, Longmont, Colorado, United States
🇺🇸
Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States
🇺🇸
Banner McKee Medical Center, Loveland, Colorado, United States

and more 430 locations

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Phase 2

Active, not recruiting

Conditions: Recurrent Primary Amyloidosis

Interventions: Drug: Dexamethasone
Drug: Cyclophosphamide
Biological: Elotuzumab
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Other: Pharmacological Study

First Posted Date: 2017-08-17

Last Posted Date: 2023-01-25

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 53

Registration Number: NCT03252600

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Levine Cancer Center, Charlotte, North Carolina, United States
🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States

and more 2 locations

Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Withdrawn

Conditions: CCND1 Positive
CD20-Positive Neoplastic Cells Present
Mantle Cell Lymphoma

Interventions: Drug: Dexamethasone
Drug: Ibrutinib
Drug: Lenalidomide
Biological: Rituximab

First Posted Date: 2017-07-27

Last Posted Date: 2019-08-22

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT03232307

Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL

Phase 2

Withdrawn

Conditions: EBV Related Non-Hodgkin's Lymphoma
Primary CNS Lymphoma
Primary Testicular Lymphoma

Interventions: Drug: Durvalumab
Drug: Lenalidomide

First Posted Date: 2017-07-11

Last Posted Date: 2018-09-13

Lead Sponsor: Singapore General Hospital

Registration Number: NCT03212807

Locations: 🇸🇬
National University Hospital, Singapore, Singapore
🇸🇬
Raffles Hospital, Singapore, Singapore
🇸🇬
Singapore General Hospital, Singapore, Singapore

and more 1 locations

Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma

Phase 1

Withdrawn

Conditions: Myeloma Multiple

Interventions: Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Pembrolizumab

First Posted Date: 2017-06-19

Last Posted Date: 2017-08-24

Lead Sponsor: University of Leeds

Registration Number: NCT03191981

Locations: 🇬🇧
University College Hospital, London, United Kingdom
🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧
Southampton General Hospital, Southampton, United Kingdom

and more 1 locations

MUK Nine b: OPTIMUM Treatment Protocol

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Lenalidomide
Drug: Daratumumab
Drug: Dexamethasone
Drug: Melphalan
Drug: Filgrastim

First Posted Date: 2017-06-15

Last Posted Date: 2024-05-14

Lead Sponsor: University of Leeds

Target Recruit Count: 95

Registration Number: NCT03188172

Locations: 🇬🇧
Bristol Haematology & Oncology Centre, Bristol, United Kingdom
🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧
Birmingham Heartlands Hospital, Birmingham, United Kingdom

and more 18 locations

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Phase 4

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2017-06-01

Last Posted Date: 2024-02-12

Lead Sponsor: Takeda

Target Recruit Count: 141

Registration Number: NCT03173092

Locations: 🇺🇸
Saint Agnes Hospital, Baltimore, Maryland, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Pacific Cancer Medical Center, Anaheim, California, United States

and more 30 locations

2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

Phase 2

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Bortezomib

First Posted Date: 2017-05-30

Last Posted Date: 2019-01-28

Lead Sponsor: University of Arkansas

Registration Number: NCT03168100

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Completed

Conditions: AML

Interventions: Drug: Etoposide
Drug: Cytarabine
Drug: Lenalidomide
Drug: Mitoxantrone

First Posted Date: 2017-04-18

Last Posted Date: 2024-04-23

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 41

Registration Number: NCT03118466

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

Phase 1

Completed

Conditions: Richter's Syndrome
CLL

Interventions: Drug: Obinutuzumab
Drug: lenalidomide
Drug: HDMP

First Posted Date: 2017-04-13

Last Posted Date: 2022-07-05

Lead Sponsor: University of California, San Diego

Target Recruit Count: 4

Registration Number: NCT03113695

Locations: 🇺🇸
University of California, San Diego, La Jolla, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy